Photo of Huihui Ye,  MD

Huihui Ye, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-5828
Fax: (617) 975-5620


hye@bidmc.harvard.edu

Huihui Ye, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Instructor, Pathology, Harvard Medical School
  • Staff Pathologist, Pathology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a practicing Urological Pathologist at the Beth Israel Deaconess Medical Center. My main research interest is to study molecular characteristics of aggressive prostate cancer, to distinguish them from indolent ones, with an ultimately goal to increase early detection and treatment of aggressive prostate cancer and to improve management of patients with indolent cancer. In collaboration with Dr. Steven Balk, one of my main projects is to identify genetic characteristics of different Gleason grades of prostate cancer and to study molecular mechanisms of progression from low to high grade cancer. A related project of mine is to study prognostic values of potential biomarkers for Gleason upgrading in active surveillance patients. In addition, I study androgen receptor signaling and resistant mechanisms in high risk prostate cancer in neoadjuvant clinical trials that patients are treated with combined Lupron and abiraterone and/or enzalutamide prior to radical prostatectomy. Revealing alternative androgen receptor signaling and other resistant mechanisms in the residual tumors will shed light on how to select sensitive patients for neoadjuvant androgen deprivation therapy and provide new drug targets for potential cure.

Publications

Powered by Harvard Catalyst
  • Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel E, Nelson PS, Taplin ME, Balk SP, Cai C. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res 2016. PubMed
  • Sadimin ET, Ye H, Epstein JI. Should the involvement of skeletal muscle by prostatic adenocarcinoma be reported on biopsies? Hum Pathol 2016; 49:10-4. PubMed
  • Quintana L, Ward A, Gerrin SJ, Genega E, Rosen S, Sanda MG, Wagner AA, Chang P, DeWolf WC, Ye H. Gleason Misclassification Rate is Independent of Number of Biopsy Cores in Systematic Biopsy. Urology 2016. PubMed
  • Wu H, Sun Y, Ye H, Yang S, Lee SL, de las Morenas A. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets. Pathol Oncol Res 2015. PubMed
  • Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res 2015. PubMed
  • Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014. PubMed
  • Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM, Beltran H, Rubin MA, Mosquera JM. Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Hum Pathol 2014; 45:2136-43. PubMed
  • Brimo F, Xu B, Scarlata E, B├ęgin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A. Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. Hum Pathol 2014; 45:2006-13. PubMed
  • Sun T, Ye H, Wu CL, Lee GS, Kantoff PW. Emerging players in prostate cancer: long non-coding RNAs. Am J Clin Exp Urol 2015; 2:294-9. PubMed
  • Sowalsky AG, Ye H, Bubley GJ, Balk SP. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res 2013; 73:1050-5. PubMed
  • Ye H, Ulbright TM. Difficult differential diagnoses in testicular pathology. Arch Pathol Lab Med 2012; 136:435-46. PubMed
  • Sheikine Y, Genega E, Melamed J, Lee P, Reuter VE, Ye H. Molecular genetics of testicular germ cell tumors. Am J Cancer Res 2012; 2:153-67. PubMed
  • Ye H, Kong X, He TW, Jolis T, Choi K, Lepor H, Melamed J. Intraoperative frozen section analysis of urethral margin biopsies during radical prostatectomy. Urology 2011; 78:399-404. PubMed
  • Ye H, Montgomery E, Epstein JI. Incidental anorectal pathologic findings in prostatic needle core biopsies: a 13-year experience from a genitourinary pathology consult service. Hum Pathol 2010; 41:1674-81. PubMed
  • Ye H, Walsh PC, Epstein JI. Skeletal muscle involvement by limited Gleason score 6 adenocarcinoma of the prostate on needle biopsy is not associated with adverse findings at radical prostatectomy. J Urol 2010; 184:2308-12. PubMed
  • Miller JS, Chen Y, Ye H, Robinson BD, Brimo F, Epstein JI. Extraprostatic extension of prostatic adenocarcinoma on needle core biopsy: report of 72 cases with clinical follow-up. BJU Int 2010; 106:330-3. PubMed
  • Miyamoto H, Brimo F, Schultz L, Ye H, Miller JS, Fajardo DA, Lee TK, Epstein JI, Netto GJ. Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med 2010; 134:1160-3. PubMed
  • Zavadil J, Ye H, Liu Z, Wu J, Lee P, Hernando E, Soteropoulos P, Toruner GA, Wei JJ. Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PLoS ONE 2010; 5:e12362. PubMed
  • Lotan TL, Ye H, Melamed J, Wu XR, Shih IeM, Epstein JI. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol 2010; 33:1037-41. PubMed
  • Ye H, Yoon GS, Epstein JI. Intrarenal ectopic adrenal tissue and renal-adrenal fusion: a report of nine cases. Mod Pathol 2009; 22:175-81. PubMed
  • Ye H, Li Y, Melamed J, Pearce P, Wei J, Chiriboga L, Wang Z, Osman I, Lee P. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer. J Urol 2009; 181:872-7. PubMed
  • Li Y, Li CX, Ye H, Chen F, Melamed J, Peng Y, Liu J, Wang Z, Tsou HC, Wei J, Walden P, Garabedian MJ, Lee P. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med 2009; 12:2790-8. PubMed
  • Ye H, Losada M, West AB. Diverticulosis coli: update on a "Western" disease. Adv Anat Pathol 2005; 12:74-80. PubMed
  • Ye H, Choi HJ, Poe J, Smithgall TE. Oligomerization is required for HIV-1 Nef-induced activation of the Src family protein-tyrosine kinase, Hck. Biochemistry 2004; 43:15775-84. PubMed
  • Ren G, Yu X, Li Y, Shi S, Wang L, Ye H. Juxtaglomerular cell tumor of the kidney: a clinicopathological analysis of five cases. Chin Med J (Engl) 2003; 116:1789-92. PubMed
Hide